6:28 PM
 | 
Nov 13, 2012
 |  BC Extra  |  Company News

Oncology Venture gains rights to Topotarget's APO010

Newco Oncology Venture ApS (Copenhagen, Denmark) debuted on Tuesday and acquired exclusive, worldwide rights from Topotarget A/S (CSE:TOPO) to APO010, a recombinant...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >